News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
633,807 Results
Type
Article (54561)
Company Profile (174)
Press Release (579072)
Section
Business (176457)
Career Advice (2950)
Deals (33861)
Drug Delivery (112)
Drug Development (77090)
Employer Resources (175)
FDA (15947)
Job Trends (14868)
News (314319)
Policy (34395)
Tag
Academia (2791)
Alliances (50996)
Alzheimer's disease (1283)
Approvals (15860)
Artificial intelligence (144)
Bankruptcy (332)
Best Places to Work (11331)
Biotechnology (120)
Breast cancer (124)
Cancer (1123)
Cardiovascular disease (105)
Career advice (2467)
Cell therapy (251)
Clinical research (61053)
Collaboration (399)
Compensation (175)
COVID-19 (2765)
C-suite (91)
Data (1103)
Diabetes (163)
Diagnostics (6246)
Drug pricing (98)
Earnings (61464)
Employer resources (152)
Events (84541)
Executive appointments (297)
FDA (16480)
Funding (349)
Gene therapy (191)
GLP-1 (678)
Government (4791)
Healthcare (18269)
Infectious disease (2858)
Inflammatory bowel disease (110)
Interviews (557)
IPO (15339)
Job creations (3879)
Job search strategy (2082)
Layoffs (476)
Legal (9082)
Lung cancer (183)
Manufacturing (194)
Medical device (12291)
Medtech (12295)
Mergers & acquisitions (18610)
Metabolic disorders (458)
Neuroscience (1582)
NextGen Class of 2024 (6522)
Non-profit (4664)
Northern California (1370)
Obesity (267)
Opinion (237)
Patents (109)
People (49955)
Phase I (18496)
Phase II (26672)
Phase III (20881)
Pipeline (462)
Postmarket research (2533)
Preclinical (7791)
Radiopharmaceuticals (242)
Rare diseases (222)
Real estate (5950)
Regulatory (21914)
Research institute (2468)
Resumes & cover letters (462)
Southern California (1177)
Startups (3553)
United States (12251)
Vaccines (644)
Weight loss (215)
Date
Today (74)
Last 7 days (644)
Last 30 days (3472)
Last 365 days (33935)
2024 (31074)
2023 (37947)
2022 (48856)
2021 (52954)
2020 (51925)
2019 (45793)
2018 (34886)
2017 (31975)
2016 (30895)
2015 (35495)
2014 (28599)
2013 (25056)
2012 (24895)
2011 (25475)
2010 (23009)
Location
Africa (952)
Arizona (133)
Asia (39123)
Australia (6667)
California (3035)
Canada (1207)
China (258)
Colorado (139)
Connecticut (137)
Europe (90295)
Florida (436)
Georgia (111)
Illinois (338)
Indiana (174)
Maryland (545)
Massachusetts (2189)
Michigan (158)
Minnesota (200)
New Jersey (904)
New York (901)
North Carolina (690)
Northern California (1370)
Ohio (137)
Pennsylvania (779)
South America (1317)
Southern California (1177)
Texas (426)
Utah (95)
Washington State (328)
633,807 Results for "hoffmann la roche ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Columvi (glofitamab for injection) receives positive CADTH and INESSS recommendations for adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL)
Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on March 5, 2024, the Institut National d’Excellence en Santé et en Services Sociaux (INESSS) recommended Columvi® (glofitamab for injection) for public reimbursement.
March 7, 2024
·
6 min read
Weight loss
Roche’s Obesity Pill Candidate Hit With Safety Concerns Despite Strong Efficacy Data
When doses were increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal distension.
September 12, 2024
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Roche Looks to Push Gazyva Into Lupus Nephritis With Promising Late-Stage Data
In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the indication.
September 27, 2024
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Roche Trims Another Alzheimer’s Prospect, Ending UCB Collabortion
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
October 22, 2024
·
1 min read
·
Annalee Armstrong
Regulatory
Roche Reintroduces Wet AMD Eye Implant Nearly Two Years After Voluntary Recall
Roche’s eye implant Susvimo for patients with neovascular age-related macular degeneration is re-entering the U.S. market after the FDA approved updates to the components of the product.
July 9, 2024
·
2 min read
·
Tristan Manalac
Earnings
Roche Beats Q3 Sales Estimates as CEO Voices Opposition to Novo Holdings’ Catalent Buyout
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by strong performance of its multiple sclerosis therapy Ocrevus and eye injection Vabysmo.
October 23, 2024
·
3 min read
·
Tristan Manalac
Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for VABYSMO® (faricimab injection) for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
Hoffmann-La Roche Limited announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for VABYSMO®, indicated for the treatment of neovascular age-related macular degeneration and diabetic macular edema,1 two of the leading causes of vision loss among Canadians.
May 29, 2023
·
5 min read
M&A
Roche Doubles Down on Breast Cancer With $850M for Regor’s CDK Inhibitors
The acquisition was featured Monday in Roche’s Pharma Day presentation, which also included projections of more than $3 billion in annual sales from three early-stage obesity and diabetes drugs.
September 30, 2024
·
2 min read
·
Heather McKenzie
Deals
Roche Inks Potential $1.8B Deal With Flare to Target Transcription Factors in Cancer
With $70 million upfront and more than $1.8 billion on the line, Roche will gain access to Flare’s drug discovery engine to bolster its oncology pipeline.
November 12, 2024
·
2 min read
·
Tristan Manalac
Approvals
Roche Wins First-Line Breast Cancer Nod for Oral PI3K Blocker, Projects $2.3B in Peak Sales
With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K inhibitor Piqray, which last year generated $505 million in revenue.
October 11, 2024
·
2 min read
·
Tristan Manalac
1 of 63,381
Next
